Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 1 24Phase NA 16Phase 1/2 15Phase 3 8Phase 4 4Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 86Glioblastoma 82Pancreatic Neoplasms 76Glioma 66Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 55Colorectal Neoplasms 55Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 51Recurrence 47Squamous Cell Carcinoma of Head and Neck 46Ovarian Neoplasms 45Lymphoma 40Lymphoma, Non-Hodgkin 37Sarcoma 36Lymphoma, B-Cell 36Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 34Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

sacubitril and valsartan sodium hydrate drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Medullary × Clear all
NCT03647657 2022-02-10

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Completed
8 enrolled
EndocrineHead & Neck

Thyroid cancer, medullary, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡